A harder question can change the story
We put four compounds beside tougher questions. These comparisons follow the evidence, which doesn't always follow the publication dates.
Compare the questions, then the results
What does each kind of test actually tell us?
The finding that gets our attention
An early experiment can be useful without proving a treatment works. Maybe it shows a molecule acting on a cell. Maybe it finds that something gets into skin. Those are fair questions to study.
Retatrutide's cell and receptor work helps explain its three hormone targets. A GHK-Cu experiment measured copper getting through pieces of skin outside the body. Neither one tested whether a person felt better.
The leap comes when a narrow finding grows into a broad health claim. That's where we pause. What experiment would have to happen for the bigger claim to hold up?
Four harder questions, four different answers
Retatrutide had a 2023 phase 2 trial in adults with obesity or overweight with a weight-related condition. The average weight loss exceeded placebo, a dummy treatment. Digestive problems and heart-rate increases came with it. The trial preceded the 2024 receptor paper.
Thymosin alpha-1 had a larger trial for sepsis, a life-threatening response to infection. Patients and staff didn't know who received which treatment. It found no clear reduction in deaths within 28 days. The paper reported manufacturer funding.
GHK-Cu had a small 2006 test after laser skin treatment, before the 2011 delivery paper. Satisfaction was higher with the products. Measured redness, wrinkles and skin quality showed no clear improvement between groups.
MOTS-c has a registered human treatment comparison. On September 30, 2026, the registry listed it as recruiting, with no results posted. That leaves the answer open; registration doesn't establish a benefit.
There's no useful league table here
A weight change can't validate an immune claim. A skin result can't establish injection safety. We get more from comparing what changed in each story than from declaring one peptide the winner.
A few questions to take into any paper
Who took part? Look for cells, animals or people, then the condition being studied. The answer matters before any impressive percentage does.
What did researchers do? Assigning treatment by chance is different from watching people who chose it. Keeping people unaware of treatment helps limit the effect of expectations.
What changed, and what went wrong? Keep the measured result, side effects and uncertainty together. The compound stories follow those details, and the references let you reopen the papers.